IHC ER/PR Test: Comprehensive Hormone Receptor Analysis for Breast Cancer
Understanding the IHC ER/PR Test
The Immunohistochemistry Estrogen Receptor/Progesterone Receptor (IHC ER/PR) test represents a cornerstone in modern breast cancer diagnostics. This advanced laboratory analysis provides critical information about hormone receptor status in breast cancer tissue, enabling personalized treatment approaches that significantly improve patient outcomes.
What Does the IHC ER/PR Test Measure?
This specialized test detects the presence of estrogen receptors (ER) and progesterone receptors (PR) on breast cancer cells through sophisticated immunohistochemistry techniques. The analysis reveals whether cancer cells possess these specific protein receptors, which determines their responsiveness to hormone-based therapies.
- Estrogen Receptor Detection: Identifies cancer cells that grow in response to estrogen
- Progesterone Receptor Detection: Determines sensitivity to progesterone-related growth signals
- Receptor Quantification: Measures the percentage of positive cancer cells
- Staining Intensity: Assesses the strength of receptor expression
Who Should Consider IHC ER/PR Testing?
This essential diagnostic test is recommended for individuals in specific clinical situations:
Primary Diagnostic Candidates
- Newly diagnosed breast cancer patients
- Patients with suspicious breast lumps or masses
- Individuals with abnormal mammogram or ultrasound findings
- Patients undergoing breast biopsy procedures
Treatment Planning Scenarios
- Patients considering hormone therapy options
- Individuals requiring personalized treatment strategies
- Cases where targeted therapy decisions are necessary
- Patients with recurrent breast cancer
Clinical Benefits of IHC ER/PR Testing
Personalized Treatment Guidance
The test results directly influence therapeutic decisions, helping oncologists determine whether hormone-blocking medications like tamoxifen or aromatase inhibitors will be effective. This precision approach minimizes unnecessary treatments and maximizes therapeutic benefits.
Prognostic Information
ER/PR positive breast cancers generally demonstrate better prognosis and respond more favorably to treatment compared to hormone receptor-negative cancers. This information helps patients and physicians understand disease trajectory and long-term outlook.
Treatment Response Prediction
By identifying hormone-sensitive cancers, the test predicts which patients will benefit most from endocrine therapies, reducing the likelihood of ineffective treatments and associated side effects.
Understanding Your Test Results
Result Interpretation Guide
Your IHC ER/PR test report will include detailed information about receptor status:
- ER Positive/PR Positive: Cancer responds to both estrogen and progesterone, indicating excellent response to hormone therapy
- ER Positive/PR Negative: Cancer responds primarily to estrogen, still suitable for hormone-blocking treatments
- ER Negative/PR Positive: Less common pattern requiring specialized treatment consideration
- ER Negative/PR Negative: Triple-negative breast cancer requiring alternative treatment approaches
Quantitative Scoring
Results include percentage scores indicating what proportion of cancer cells test positive for each receptor, along with staining intensity measurements that help determine treatment intensity.
Test Details and Pricing
| Test Component | Details |
|---|---|
| Test Name | IHC ER/PR Test |
| Discount Price | $100 USD |
| Regular Price | $150 USD |
| Turnaround Time | 3 Days |
| Sample Type | Tissue/Paraffin Block |
| Test Components | Tissue in 10% Neutral Buffered Formalin OR Block |
Nationwide Testing Availability
GGC DNA maintains comprehensive testing facilities across major metropolitan areas throughout the United States. Our state-of-the-art laboratories serve patients in:
- New York City and surrounding regions
- Los Angeles and Southern California
- Chicago and Midwest territories
- Houston and Texas medical centers
- Major healthcare hubs nationwide
Take Control of Your Breast Cancer Journey
Understanding your hormone receptor status represents a critical step in developing an effective breast cancer treatment plan. The IHC ER/PR test provides the essential information needed to make informed decisions about your healthcare journey.
Ready to schedule your IHC ER/PR test? Contact our dedicated healthcare team today to discuss your testing needs and arrange sample collection. Call us at +1(267) 388-9828 or visit your nearest GGC DNA facility to begin your personalized diagnostic process.
Note: IHC ER/PR testing requires a doctor’s prescription in most cases. Prescription requirements may not apply for surgical cases, pregnancy-related testing, or international travel documentation needs.
